Do analysts prefer NVNO or BEAT?

HeartBeam has a consensus price target of $4.00, indicating a potential upside of 955.41%. Given HeartBeam's stronger consensus rating and higher possible upside, analysts clearly believe HeartBeam is more favorable than enVVeno Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 HeartBeam 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.56

Which has higher earnings & valuation, NVNO or BEAT?

HeartBeam is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enVVeno Medical N/A N/A -$19.47M -$19.33 N/A HeartBeam N/A N/A -$21.01M -$0.51 N/A

Is NVNO or BEAT more profitable?

enVVeno Medical's return on equity of -62.28% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets enVVeno Medical N/A -62.28% -56.83% HeartBeam N/A -686.78% -348.65%

Do analysts rate NVNO or FEMY?

Femasys has a consensus price target of $50.00, suggesting a potential upside of 1,957.61%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than enVVeno Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is NVNO or FEMY more profitable?

enVVeno Medical has a net margin of 0.00% compared to Femasys' net margin of -534.36%. enVVeno Medical's return on equity of -62.28% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets enVVeno Medical N/A -62.28% -56.83% Femasys -534.36% -225.97% -74.68%

Do analysts prefer LFWD or NVNO?

Lifeward presently has a consensus price target of $10.00, indicating a potential upside of 43.47%. Given Lifeward's higher probable upside, research analysts clearly believe Lifeward is more favorable than enVVeno Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifeward 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Is LFWD or NVNO more profitable?

enVVeno Medical has a net margin of 0.00% compared to Lifeward's net margin of -141.28%. enVVeno Medical's return on equity of -62.28% beat Lifeward's return on equity. Company Net Margins Return on Equity Return on Assets Lifeward -141.28% -235.86% -81.72% enVVeno Medical N/A -62.28% -56.83%

Do analysts recommend MODD or NVNO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Modular Medical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has better valuation & earnings, MODD or NVNO?

enVVeno Medical is trading at a lower price-to-earnings ratio than Modular Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Modular Medical N/A N/A -$28.24M -$8.69 N/A enVVeno Medical N/A N/A -$19.47M -$19.33 N/A

Is MODD or NVNO more profitable?

enVVeno Medical's return on equity of -62.28% beat Modular Medical's return on equity. Company Net Margins Return on Equity Return on Assets Modular Medical N/A -292.14% -222.79% enVVeno Medical N/A -62.28% -56.83%

Do analysts rate CTSO or NVNO?

Cytosorbents currently has a consensus price target of $107.50, suggesting a potential upside of 2,400.00%. Given Cytosorbents' higher probable upside, equities analysts clearly believe Cytosorbents is more favorable than enVVeno Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

enVVeno Medical (NVNO) Competitors

$9.09 +0.13 (+1.45%)

Closing price 04:00 PM Eastern

Extended Trading

$9.10 +0.02 (+0.17%)

As of 04:10 PM Eastern

Compare

NVNO vs. BEAT, FEMY, LFWD, MODD, and CTSO

Should you buy enVVeno Medical stock or one of its competitors? enVVeno Medical's main competitors and comparable companies include HeartBeam (BEAT), Femasys (FEMY), Lifeward (LFWD), Modular Medical (MODD), and Cytosorbents (CTSO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does enVVeno Medical compare to HeartBeam?

enVVeno Medical (NASDAQ:NVNO) and HeartBeam (NASDAQ:BEAT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

HeartBeam is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A

enVVeno Medical's return on equity of -62.28% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-62.28%	-56.83%
HeartBeam	N/A	-686.78%	-348.65%

In the previous week, HeartBeam had 12 more articles in the media than enVVeno Medical. MarketBeat recorded 13 mentions for HeartBeam and 1 mentions for enVVeno Medical. HeartBeam's average media sentiment score of -0.67 beat enVVeno Medical's score of -0.74 indicating that HeartBeam is being referred to more favorably in the news media.

Company	Overall Sentiment
enVVeno Medical	Negative
HeartBeam	Negative

enVVeno Medical has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, HeartBeam has a beta of -0.8, meaning that its share price is 180% less volatile than the broader market.

HeartBeam has a consensus price target of $4.00, indicating a potential upside of 955.41%. Given HeartBeam's stronger consensus rating and higher possible upside, analysts clearly believe HeartBeam is more favorable than enVVeno Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
HeartBeam	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

34.7% of enVVeno Medical shares are owned by institutional investors. Comparatively, 7.8% of HeartBeam shares are owned by institutional investors. 15.0% of enVVeno Medical shares are owned by company insiders. Comparatively, 18.0% of HeartBeam shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

HeartBeam beats enVVeno Medical on 7 of the 13 factors compared between the two stocks.

How does enVVeno Medical compare to Femasys?

enVVeno Medical (NASDAQ:NVNO) and Femasys (NASDAQ:FEMY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Femasys had 1 more articles in the media than enVVeno Medical. MarketBeat recorded 2 mentions for Femasys and 1 mentions for enVVeno Medical. Femasys' average media sentiment score of 0.00 beat enVVeno Medical's score of -0.74 indicating that Femasys is being referred to more favorably in the news media.

Company	Overall Sentiment
enVVeno Medical	Negative
Femasys	Neutral

Femasys has a consensus price target of $50.00, suggesting a potential upside of 1,957.61%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than enVVeno Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Femasys has higher revenue and earnings than enVVeno Medical. Femasys is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A
Femasys	$2.30M	8.85	-$18.63M	-$3.53	N/A

enVVeno Medical has a net margin of 0.00% compared to Femasys' net margin of -534.36%. enVVeno Medical's return on equity of -62.28% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-62.28%	-56.83%
Femasys	-534.36%	-225.97%	-74.68%

enVVeno Medical has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Femasys has a beta of -2.07, indicating that its share price is 307% less volatile than the broader market.

34.7% of enVVeno Medical shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 15.0% of enVVeno Medical shares are owned by insiders. Comparatively, 7.8% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Femasys beats enVVeno Medical on 9 of the 16 factors compared between the two stocks.

How does enVVeno Medical compare to Lifeward?

Lifeward (NASDAQ:LFWD) and enVVeno Medical (NASDAQ:NVNO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Lifeward has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, enVVeno Medical has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

In the previous week, Lifeward had 1 more articles in the media than enVVeno Medical. MarketBeat recorded 2 mentions for Lifeward and 1 mentions for enVVeno Medical. Lifeward's average media sentiment score of 0.00 beat enVVeno Medical's score of -0.74 indicating that Lifeward is being referred to more favorably in the media.

Company	Overall Sentiment
Lifeward	Neutral
enVVeno Medical	Negative

26.8% of Lifeward shares are owned by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are owned by institutional investors. 1.5% of Lifeward shares are owned by company insiders. Comparatively, 15.0% of enVVeno Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

enVVeno Medical has a net margin of 0.00% compared to Lifeward's net margin of -141.28%. enVVeno Medical's return on equity of -62.28% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifeward	-141.28%	-235.86%	-81.72%
enVVeno Medical	N/A	-62.28%	-56.83%

Lifeward presently has a consensus price target of $10.00, indicating a potential upside of 43.47%. Given Lifeward's higher probable upside, research analysts clearly believe Lifeward is more favorable than enVVeno Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifeward	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

enVVeno Medical has lower revenue, but higher earnings than Lifeward. enVVeno Medical is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifeward	$22.03M	0.90	-$19.91M	-$16.82	N/A
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A

Summary

enVVeno Medical beats Lifeward on 9 of the 16 factors compared between the two stocks.

How does enVVeno Medical compare to Modular Medical?

Modular Medical (NASDAQ:MODD) and enVVeno Medical (NASDAQ:NVNO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

Modular Medical has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, enVVeno Medical has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

enVVeno Medical's return on equity of -62.28% beat Modular Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Modular Medical	N/A	-292.14%	-222.79%
enVVeno Medical	N/A	-62.28%	-56.83%

enVVeno Medical is trading at a lower price-to-earnings ratio than Modular Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Modular Medical	N/A	N/A	-$28.24M	-$8.69	N/A
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A

In the previous week, Modular Medical and Modular Medical both had 1 articles in the media. Modular Medical's average media sentiment score of 0.67 beat enVVeno Medical's score of -0.74 indicating that Modular Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Modular Medical	Positive
enVVeno Medical	Negative

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Modular Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

27.5% of Modular Medical shares are held by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are held by institutional investors. 7.1% of Modular Medical shares are held by insiders. Comparatively, 15.0% of enVVeno Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

enVVeno Medical beats Modular Medical on 8 of the 11 factors compared between the two stocks.

How does enVVeno Medical compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and enVVeno Medical (NASDAQ:NVNO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

In the previous week, Cytosorbents had 2 more articles in the media than enVVeno Medical. MarketBeat recorded 3 mentions for Cytosorbents and 1 mentions for enVVeno Medical. Cytosorbents' average media sentiment score of 0.58 beat enVVeno Medical's score of -0.74 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Overall Sentiment
Cytosorbents	Positive
enVVeno Medical	Negative

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are held by institutional investors. 7.8% of Cytosorbents shares are held by company insiders. Comparatively, 15.0% of enVVeno Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cytosorbents has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market. Comparatively, enVVeno Medical has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

enVVeno Medical has a net margin of 0.00% compared to Cytosorbents' net margin of -48.94%. enVVeno Medical's return on equity of -62.28% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-48.94%	-431.65%	-41.94%
enVVeno Medical	N/A	-62.28%	-56.83%

Cytosorbents has higher revenue and earnings than enVVeno Medical. Cytosorbents is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.37	-$8.20M	-$5.80	N/A
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A

Cytosorbents currently has a consensus price target of $107.50, suggesting a potential upside of 2,400.00%. Given Cytosorbents' higher probable upside, equities analysts clearly believe Cytosorbents is more favorable than enVVeno Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Cytosorbents beats enVVeno Medical on 9 of the 16 factors compared between the two stocks.

Get enVVeno Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVNO vs. The Competition

Export

Metric	enVVeno Medical	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.32M	$5.49B	$7.26B	$13.10B
Dividend Yield	N/A	1.79%	2.52%	12.57%
P/E Ratio	-0.47	25.36	274.69	25.75
Price / Sales	N/A	89.55	679.25	97.61
Price / Cash	N/A	33.02	77.80	52.76
Price / Book	0.22	5.74	10.52	6.34
Net Income	-$19.47M	$151.55M	$3.49B	$360.00M
7 Day Performance	2.77%	-0.36%	-1.08%	-0.10%
1 Month Performance	-12.17%	-3.97%	-3.39%	-3.41%
1 Year Performance	-73.34%	5.74%	15.08%	5.46%

enVVeno Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVNO enVVeno Medical	1.8 of 5 stars	$9.09 +1.5%	N/A	-73.2%	$6.32M	N/A	N/A	33	Gap Down
BEAT HeartBeam	3.0998 of 5 stars	$0.41 -3.7%	$4.00 +877.0%	-76.1%	$23.95M	N/A	N/A	1,700	Trending News Analyst Downgrade Analyst Revision
FEMY Femasys	2.8167 of 5 stars	$2.54 -0.8%	$50.00 +1,868.5%	-62.5%	$21.44M	$2.29M	N/A	30	News Coverage
LFWD Lifeward	1.9492 of 5 stars	$6.91 -2.3%	$10.00 +44.7%	-13.7%	$20.02M	$22.03M	N/A	60
MODD Modular Medical	1.1545 of 5 stars	$2.31 -4.1%	N/A	-89.7%	$19.64M	N/A	N/A	20	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVNO) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

enVVeno Medical (NVNO) Competitors

NVNO vs. BEAT, FEMY, LFWD, MODD, and CTSO

How does enVVeno Medical compare to HeartBeam?

Summary

How does enVVeno Medical compare to Femasys?

Summary

How does enVVeno Medical compare to Lifeward?

Summary

How does enVVeno Medical compare to Modular Medical?

Summary

How does enVVeno Medical compare to Cytosorbents?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVNO vs. The Competition

enVVeno Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

enVVeno Medical (NVNO) Competitors

NVNO vs. BEAT, FEMY, LFWD, MODD, and CTSO

How does enVVeno Medical compare to HeartBeam?

Which has higher earnings & valuation, NVNO or BEAT?

Is NVNO or BEAT more profitable?

Does the media favor NVNO or BEAT?

Which has more volatility and risk, NVNO or BEAT?

Do analysts prefer NVNO or BEAT?

Do institutionals & insiders hold more shares of NVNO or BEAT?

Summary

How does enVVeno Medical compare to Femasys?

Does the media favor NVNO or FEMY?

Do analysts rate NVNO or FEMY?

Which has stronger valuation and earnings, NVNO or FEMY?

Is NVNO or FEMY more profitable?

Which has more risk and volatility, NVNO or FEMY?

Do insiders & institutionals believe in NVNO or FEMY?

Summary

How does enVVeno Medical compare to Lifeward?

Which has more volatility & risk, LFWD or NVNO?

Does the media refer more to LFWD or NVNO?

Do insiders and institutionals believe in LFWD or NVNO?

Is LFWD or NVNO more profitable?

Do analysts prefer LFWD or NVNO?

Which has better earnings and valuation, LFWD or NVNO?

Summary

How does enVVeno Medical compare to Modular Medical?

Which has more volatility & risk, MODD or NVNO?

Is MODD or NVNO more profitable?

Which has better valuation & earnings, MODD or NVNO?

Does the media refer more to MODD or NVNO?

Do analysts recommend MODD or NVNO?

Do insiders & institutionals believe in MODD or NVNO?

Summary

How does enVVeno Medical compare to Cytosorbents?

Does the media refer more to CTSO or NVNO?

Do insiders & institutionals believe in CTSO or NVNO?

Which has more volatility and risk, CTSO or NVNO?

Is CTSO or NVNO more profitable?

Which has stronger earnings and valuation, CTSO or NVNO?

Do analysts rate CTSO or NVNO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVNO vs. The Competition

enVVeno Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools